Duke University Medical Center
Durham, North Carolina, 27705, United States
NCT Number: NCT00218595
The purpose of this study is to examine the efficacy of DBT compared to a standard drug counseling approach for the treatment of opiate addiction and borderline personality disorder (BPD). Treatment research has repeatedly shown that retention of BPD and substance addicted individuals to be the among the most challenging for therapists. DBT has established itself as one of the most effective treatments for treatment retention of these patients and for reducing parasuicidal and self-injurious behaviors.
This study is one of two in a multi-site RCT for the treatment of opiate addiction. DBT has been shown to be efficacious for the treatment of BPD patients and it has been extended in this study to target addictive behaviors in these patients. The study consists of three treatment parts: weekly individual and group therapy and suboxone maintenance medication. Participants are provided therapy on a weekly basis for one year and suboxone for 2 years. Assessments for tracking outcome are conducted every 4 months.
It is hypothesized patients in the DBT condition will show a reduction of substance use, parasuicidal and other psychological difficulties and these gains will be maintained through the year of follow-up assessments. In addition, it is predicted that adherence to DBT treatment protocols will be associated with improved outcomes. Finally, it is predicted that treatment "dosage" (average hours of therapy/week) will be positively related to clinical improvement.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Durham, North Carolina, 27705, United States
The study design is a two arm randomized clinical trial comparing a one year treatment program of Dialectical Behavior Therapy (DBT) + suboxone for heroin addicted individuals meeting criteria for borderline personality disorder (BPD) to a one year program of standard drug counseling (I/GDC) + suboxone. Drug counseling will consist of manualized individual sessions + group therapy. Participants in both conditions will be prescribed psychotropic medications following a standardized medication protocol developed specifically for BPD individuals. Each site will enroll 86 clients with both treatment conditions being conducted at each site. Assessments measuring drug use, suicidal behaviors, retention and other treatment-related behaviors, general psychopathology and functioning, and increases in behavioral skills will be given at four month intervals for two years
There are five outcome domains of principal interest in this study:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dialectical behavior therapy plus opiate replacement medication.
Individual and group drug counseling plus opiate replacement medication.
Time frame: Baseline, 4-month, 8-month, 12-month, 16-month, 20-month, 24-month
Time frame: 3x/week during active treatment; 1x/week during follow-up year
Time frame: 1x/week during active treatment
Duke University
Other
Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05741268
Dialectical Behavior Therapy
Alexandria, Egypt
View Trial DetailsNCT07693439
Chemically-Induced Disorders, Dialectical Behavior Therapy
Ålesund, More and Romsdal, Norway
View Trial DetailsNCT07239362
Behavior, Behavioral Symptoms
Lahore, Punjab Province, Pakistan
View Trial Details